Hemispherx BioPharma, Inc Stock Nyse
Equities
US42366C1036
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 2.57M | Capitalization | 23.8M |
---|---|---|---|---|---|
Net income 2024 * | -27M | Net income 2025 * | -28M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 9.26 x |
P/E ratio 2024 * |
-0.88
x | P/E ratio 2025 * |
-1.01
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.01% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 22-04-03 |
Chief Tech/Sci/R&D Officer | - | 22-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 23-03-27 |
William Mitchell
CHM | Chairman | 89 | 98-06-30 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 08-11-16 |
1st Jan change | Capi. | |
---|---|---|
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.22% | 21.66B | |
-18.35% | 20.77B | |
-8.12% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |